Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Estrogen Replacement Therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 282876
Acolbifene is the chemical compound known as acolbifene hydrochloride, which has the following chemical structure
[2H-1-Benzopyran-7-ol, 3-( 4-hydroxyphenyl)-4-methyl-2-[ 4-[2-(lpiperidinyl)ethoxy]phenyl]-, hydrochloride, (2S)~]and may be alternatively described as
[ (2S)-3-( 4-Hydroxyphenyl)-4-methyl-2-[ 4-(2-piperidin-1-yl-ethoxy)phenyl]-2Hchromen-7-ol]
Acolbifene belongs to a class of compounds known as selective estrogen receptor modulators, or SERMs. SERMs inhibit the stimulatory effect that the female sex hormone estrogen has on the growth of breast and uterine cancer.
Field means the therapeutic and/or prophylactic use of any Licensed Compound or Licensed Product for the treatment of any disease or condition in humans and/or animals.
IPSCIO Record ID: 283199
The Parties have been collaborating in the development of a certain antiestrogen compound as a Licensed Compound under the terms of the Agreement.
Licensee now desires to assume sole responsibility for the continued development of such antiestrogen compound.
Licensed products means any pharmaceutical products in dosage form which contain one or more Licensed Compounds, including without limitation, Licensed Combinations.
Licensed Compounds means (i) any compounds existing on the effective date of this Agreement which were conceived of as antiestrogen or antiandrogen compounds by or on behalf of Licensee and (ii) any additional novel or existing compounds which are conceived of as compounds in the Field by or on behalf of Licensee while carrying out research in the program as that term is defined.
IPSCIO Record ID: 385608
Fablyn means lasofoxifene tartrate. Fablyn (lasofoxifene tartrate) is a selective estrogen receptor modulator (SERM) intended for the treatment of osteoporosis in postmenopausal women.
IPSCIO Record ID: 314345
Licensee shall have the right to sublicense the rights granted to it under this Agreement to any third party or parties.
is dramatically decreased. Subsequently elderly women develop commonly climacteric symptoms including hot flushes, sweating, insomnia, depression, headache, vaginal dryness, cardiovascular symptoms, urinary incontinence, swelling feeling, breast tenderness and fatigue. In long-term estrogen deficiency induces cardiovascular disorders and osteoporosis which increase the risk of bone fractures and hospitalizations.
Patents shall mean granted US patent No 6,576,645 and its divisional allowed US patent application No 10/408,303, both titled 'Triphenylalkene derivatives and their use as selective estrogen receptor modulators' and any corresponding issued patent or filed patent application based on the inventions described in US patent 6,576,645 or the US patent application 10/408,303 that are filed or granted in any country of the world including any corresponding patent applications filed in any country or territory, or based on any divisionals, continuations, continuations-in-part, reissues, re-examinations, and extensions of any of the foregoing (including any 'patent term restoration' period or supplementary protection certificate granted under applicable laws in a given country).
Patent #6,576,645 – Triphenylalkene derivatives and their use as selective estrogen receptor modulators
Product(s) shall mean any pharmaceutical product containing i) any of the compounds identified in the Invention as its active ingredient alone or in combination of other active ingredients; ii) any molecule that has similar pharmacological properties with such compounds and falls within the claims of the Patents.
Licensee a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas relating to the treatment of hormone deficiencies that result from aging in men and women.
IPSCIO Record ID: 385707
Licensor grants an exclusive license to the Licensed Compounds under the Licensed Patents and Licensed Know-How to research, develop, have developed, make, have made, use, have used, manufacture, have manufactured, register, have registered, offer for sale, sell, have sold, import and export, distribute, and market Licensed Products in the Field within the Territory. Licensee shall have the right to sublicense.
Licensee shall have an exclusive option to license exclusively the rights related to such Compound in the Field under a separate, definitive license agreement.
The Licensors Compounds considered and/or evaluated by Licensee under the Agreement and are selected by Licensee to be licensed, the Licensed Compounds.
An Early Preclinical Compound shall be defined as a Compound for which there is less than 4-week GLP toxicology studies in at least two animal species, including at least one rodent species and one non-rodent species.
A Late Preclinical Compound shall be defined as a Compound for which there is at least 4-week GLP toxicology studies in at least two animal species, including at least one rodent species and one non-rodent species, but no human clinical data.
A Clinical Compound shall be defined as a Compound for which there is at least 4-week GLP toxicology studies in at least two animal species, including at least one rodent species and one non-rodent species, and at least one human clinical study conducted under a US IND or equivalent, and covering at least twenty-eight days of daily dosing.
The licensed patents are all existing and future patents and patent applications relating to the Licensed Compounds.
The licensed products are any pharmaceutical formulation which contains a Licensed Compound for use in the Field, including any metabolites, salts, isomers, or pro-drugs of a Licensed Compound.
The field of use is Diagnostic uses, topical treatments for cosmetic uses and topical treatments for the prevention, amelioration, or cure of dermatological diseases, including without limitation, skin cancers, and conditions in humans and animals.